In conclusion, TOPK seems to be a valuable prognostic factor in patients with sporadic CRC with KRAS or BRAF gene mutations, as well as in patients with metastatic disease who respond to anti-EGFR therapies. This evidence concerns the gene PBK and colorectal carcinoma.